Bonnie Wang, MS, DABT (she/her/hers)

Associate Director
Bristol Myers Squibb

Poster(s):

• (M-118) Past as Prologue: A Novel Anti-Fucosyl-GM1 Monoclonal Antibody in Extended Stage Small Cell Lung Cancer (ES-SCLC) Phase 3 Dose Selection through Exposure/Dose-Response Analyses of Efficacy and Safety
  Monday, November 11, 2024

  7:00 AM – 5:00 PM MST

• (M-119) Population Pharmacokinetic (popPK) of BMS-986012, a Novel Anti-Fucosyl-GM1 Monoclonal Antibody, in Patients with First-Line and Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
  Monday, November 11, 2024

  7:00 AM – 5:00 PM MST